On September 18, WUXI BIO rose 3.09% in regular trading, trading at HK$51.65/share, with turnover of HK$393 million.

On the news front, the CXO sector extended its rally as global pharmaceutical R&D outsourcing rates surpassed 50%, signaling robust structural demand. The company reported strong first-half results with revenue of RMB 11.787 billion, up 18.4% year-over-year, while adjusted net profit attributable to shareholders surged 38.4%. Management raised full-year revenue growth guidance to 15%-18%, supported by an unfilled order backlog of approximately US$5.5 billion, up around 30% year-over-year. The gross margin improved from 42.7% to 46.2%.

Multiple brokerages recently raised target prices, including CICC and CMBI International at HK$60, Daiwa at HK$59, and Guotai Junan International at HK$64.53, all maintaining buy ratings. Within the Life Sciences Tools and Services sector, INSILICO rose 11.72%, JOINN rose 9.80%, XTALPI rose 9.43%, GENSCRIPT BIO rose 6.56%, and WUXI APPTEC rose 2.73%, reflecting broad sector strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)